Have a question? Book your consultation on WhatsApp — we reply in minutes.

Book on WhatsApp
Retatrutide Thailand — Triple Agonist GLP-1/GIP/Glucagon
Recommandé par le Médecin
Investigational Peptide · Research Use

Retatrutide Thailand — Triple Agonist GLP-1/GIP/Glucagon

Healthi Life · Ekkamai 10, Bangkok

Retatrutide is an investigational triple agonist of GLP-1, GIP and glucagon receptors (Eli Lilly, Phase III TRIUMPH program). At Healthi Life in Thailand it is offered exclusively for medical research and under strict physician supervision, with biomarker monitoring and documented informed consent. Prescription medicine — dispensed only after an in-person consultation and a prescription issued by a licensed physician.

À partir de฿10,000

Per vial (includes consultation & biomarker review)

Réserver une ConsultationWhatsAppCall +66 91 999 1744
Physician-Supervised
Biomarker-Monitored
Prescription Only
Ekkamai, Bangkok

Ce Qui Est Inclus

Physician consultation with research-use informed consent
Extended baseline and monthly biomarker review
Injection guidance and adverse-event monitoring
Pourquoi Choisir Ce Protocole

How Retatrutide Is Studied

Triple Agonist Mechanism

Retatrutide targets GLP-1, GIP and glucagon receptors simultaneously — an investigational pathway studied for its effects on appetite, blood-sugar control, energy expenditure and metabolism.

Physician-Supervised

Used strictly under physician oversight at Healthi Life Ekkamai with documented informed consent.

Biomarker-Monitored

Extended baseline labs and monthly follow-up frame every titration decision.

Contraindication Review

Personal and family history screening before initiation, with explicit exclusion criteria.

Subcutaneous Administration

Weekly subcutaneous injection with in-clinic guidance and adverse-event monitoring.

Research Framework

Offered exclusively for medical research and structured longevity programs, never as cosmetic use.

Est-Ce Fait Pour Vous ?

Idéal Pour

  • Adults with documented medical eligibility and informed consent
  • Guests committed to extended baseline biomarkers and monthly follow-up
  • Candidates integrated into a physician-led longevity or metabolic program

Non Recommandé Pour

  • Pregnant, planning pregnancy, or breastfeeding women
  • Personal or family history of medullary thyroid carcinoma (MTC) or MEN-2
  • Active pancreatitis or severe gastrointestinal disease
  • Severe hepatic or renal impairment without specialist clearance
Votre Parcours

Our 4-Step Retatrutide Program

1

Medical Intake & Consent

Full history, contraindication screening and signed research-use informed consent.

2

Extended Baseline

HbA1c, lipid panel, glucagon, hepatic and renal function established before initiation.

3

Titration

Progressive dose escalation under physician supervision based on tolerability and response.

4

Monthly Follow-Up

Clinical review, adverse-event monitoring and biomarker reassessment every four weeks.

Excellence Médicale

Pourquoi Faire Confiance à Healthi Life

Protocoles dirigés par des médecins, certifications internationales et un engagement envers la sécurité des guests à Bangkok.

ISO 9001:2015 Certified Partner Labs
GMP Compliant Partner Laboratory
Thai Medical Council Registered
International Guest Safety Standards

Regulatory status

Retatrutide is an investigational medicine. It is not FDA approved, and it is not a commercially approved medicine in Thailand — it is in Phase III development (Eli Lilly, TRIUMPH program). It is therefore not available over the counter, online, or from a non-medical seller, and it is not offered here as a commercial or cosmetic product. At Healthi Life it is used only inside a licensed medical facility, under physician supervision, within a research and structured longevity framework, and only after documented informed consent. Registration status of any medicinal product in Thailand can be checked with the Thai Food and Drug Administration (อย.). Trial results do not guarantee individual outcomes and long-term safety is still being evaluated.

Exclusion criteria: pregnancy, planning pregnancy or breastfeeding; personal or family history of medullary thyroid carcinoma or MEN-2; active pancreatitis or severe gastrointestinal disease; severe hepatic or renal impairment without specialist clearance.

Programmes

Choisissez Votre Programme

RECOMMANDÉ

Retatrutide — 1 vial

฿10,000

  • 1 vial (research use)
  • Physician consultation
  • Baseline biomarker review
  • Injection guidance & adverse-event monitoring
Sélectionner ce Programme
FAQ

Questions Fréquemment Posées

Retatrutide is an investigational peptide developed by Eli Lilly. It acts as a triple agonist of the GLP-1, GIP and glucagon receptors and is currently in Phase III trials (TRIUMPH program) for chronic weight management.

In a Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) involving 338 adults, participants on the highest retatrutide dose experienced an average weight reduction of about 24% at 48 weeks, alongside improvements in glycemic and lipid markers. Retatrutide remains investigational: trial results do not guarantee individual outcomes, and larger Phase 3 studies (the TRIUMPH program) are ongoing to confirm efficacy and long-term safety.

No. Retatrutide is not FDA approved. It remains an investigational medicine under clinical development. At Healthi Life Bangkok it is offered exclusively for medical research and under strict physician supervision.

At Healthi Life Ekkamai, Retatrutide is priced at ฿10,000 per vial. This includes physician consultation, baseline biomarker review and injection guidance with adverse-event monitoring.

Mounjaro (Tirzepatide) is a dual GIP/GLP-1 receptor agonist approved by the FDA. Retatrutide adds glucagon-receptor agonism as a third mechanism and is still investigational. Their evidence base, regulatory status and use cases differ.

Eligibility requires documented medical indication, contraindication review and signed research-use informed consent. Pregnancy, MTC/MEN-2 history, pancreatitis, and severe hepatic or renal impairment are exclusion criteria.

Published trials (NEJM 2023, Jastreboff et al.; Lancet 2023) report predominantly gastrointestinal effects: nausea, diarrhea, vomiting and decreased appetite, mostly during titration. Long-term safety continues to be evaluated.

Retatrutide is investigational worldwide and is not a commercially approved medicine in Thailand. At Healthi Life it is offered solely within a physician-supervised research and longevity framework, with documented consent.

Yes. At Healthi Life, Retatrutide is integrated with extended biomarker tracking — HbA1c, lipid panel, glucagon, hepatic and renal function — reviewed monthly alongside the broader longevity program.

Mounjaro (Tirzepatide) is a dual GIP/GLP-1 receptor agonist approved by the FDA. Retatrutide adds glucagon-receptor agonism as a third mechanism and is still investigational. Their evidence base, regulatory status and use cases differ.

This is a prescription medicine and must be initiated by a licensed physician. At Healthi Life Bangkok, prescription is preceded by an in-person consultation covering medical history, contraindication screening and baseline laboratory testing. Because the molecule is investigational, a signed research-use informed consent is also required. There is no over-the-counter, online or walk-in supply.

Medically reviewed by Dr. Petch & Dr. First

Dr. Petch — International Board of Lifestyle Medicine (IBLM) — Diplomate

Dr. First — Dermatologist & Peptides Specialist

Last reviewed: July 1, 2026

Cette page fournit une information générale et ne constitue ni un avis médical, ni un diagnostic, ni un traitement. Les résultats varient d'une personne à l'autre. ⁨Retatrutide (investigational GLP-1/GIP/glucagon agonist), tirzepatide — Mounjaro⁩ est un médicament soumis à prescription, délivré et administré uniquement après évaluation par un médecin agréé. Cette page est une information médicale, non une publicité ni une offre de soin. Consultez toujours un médecin qualifié au sujet de votre état de santé. Voir notre avertissement médical complet.

Book a Retatrutide Consultation

Speak with a physician at Healthi Life Ekkamai for eligibility review, informed consent and an extended baseline biomarker plan.

Localisation

94 Ekkamai 10 Alley, Khlong Tan Nuea, Watthana, Bangkok 10110

5 min by taxi from BTS Ekkamai

Horaires

Mon-Sat: 11:00 AM – 7:00 PM

Temps de réponse : moins de 2 heures

Réserver une ConsultationContactez-nous sur WhatsApp+66 91 999 1744

Services associés

Découvrez les autres soins qui complètent votre parcours

Medical Weight Loss Hub

Compare Mounjaro · Wegovy · Retatrutide

En savoir plus

Recovery & Performance

All recovery & performance treatments

En savoir plus

Ozempic Bangkok

Semaglutide (Ozempic) GLP-1 care

En savoir plus

Mounjaro Bangkok

Tirzepatide dual GIP/GLP-1 program

En savoir plus

Wegovy Bangkok

Semaglutide GLP-1 program

En savoir plus

Peptide Therapy

Physician-led peptide programs

En savoir plus